By Ameriya l’Agusta, MD, PhD; Ecth Tirian, PhD; Thaila Lemrenoy, MD; Mizhir Devara, MD; Ashlynn Jakuard, MD.
The unique structure of the Deathglow booster, imparted by a double bond of carbon-13 atoms each containing a pentaquark ‘Notron,’ contributes to the effective nature of the drug. The treatment of patients affected by Deathglow mostly relies upon conventional methods, though they are less effective when compared to less exotic hallucinogens.
Deathglow is an organic acid, similar to another more banal hallucinogen, but boosted by the addition of a Chromodynamic Tricarboxyl group bonded to an exotic carbon-13 atom in the main structure. This bond, which comes in at least three types, acts in some unknown way to increase the effect of the booster. A similar structure without the exotic baryons in the C-13 atoms yields a chemical that is toxic to the human body in high doses, but otherwise has no observed side effects.
This carbon-13 atom contains six neutrons, six neutrons and one pentaquark baryon that acts as a neutron, but is not. The particle physicist Dr. Tirian has nicked named these baryons ‘Notrons.’ So far two ‘Notrons’ have been been observed; they have been named Red and Yellow.
These Notrons form a second bond in addition to the normal chemical bond between the 2 carbon-13 atoms. These bonds come in three ‘colours’: Red, Orange, and Yellow. So far, the exact nature of the bonds is still being researched.
What is known is that the color of the bond relates to the stability, or instability of the Notrons. Two Red Notrons form a Red bond. Two Yellow Notrons form a Yellow bond. A combination of each forms an Orange bond. Any bond other than Red is unstable, ultimately resulting in a breakdown of the Notrons. The Notrons break down into a proton, changing carbon-13 to nitrogen-13. Though nitrogen-13 decays back into carbon-13, the temporary atomic change is enough to shatter the Deathglow structure into mostly random hydrocarbons. These decay products are highly toxic.
Deathglow can also be neutralized by conventional bases, such as sodium bicarbonate or sodium hydroxide. Again, the results are usually quite toxic, including methane and carbon monoxide. Any persons neutralizing Deathglow should use the appropriate protective equipment.
Absorption and Effects on the Body:
Deathglow is absorbed through mucous membranes. Weaponized Deathglow is most effectively delivered by aerosol, suspended in water. Common protective measures, such a military gas masks, or enclosed breathing systems have proven highly effective in keeping users from being affected by Deathglow.
The exact way that Deathglow affects the brain is unknown. This is typical of most psychopharma. Because of this, and the current lack of human testing, the efficacy of any possible antidote is unknown. This group does not look favorably on the use of field conditions to conduct tests on affected persons.
As little as 1µg of Deathglow has been seen to produce effects in animal subjects. Currently, the prescribed treatment is to sedate any person affected until the body excretes the Deathglow naturally. It is passed renaly, the time dependant upon the dose received. Testing is ongoing with artificial and animal subjects to determine the rate at which doses wear off. So far, Deathglow’s effects has not been observed to last longer than 96 hours. Sedative doses should be planned for at least 120 hours, with a 15% increase over baseline doses.
LD50 for Deathglow is 250mg/kg based on best data as of current. That number is being refined, but we are confident to ±15mg/kg. This number is incredibly high and has been difficult to administer to animal and artificial test subjects. Aerosol Deathglow (in an aqueous solution) with concentrations of 200mg/m3 took 30 hours on average to kill 8 artificial human subjects.
At this time, the group is unable to determine the exact effects upon the human mind with regards to the reported aggression and tendency for affected persons to attack others at random. Effects observed on animals do indicate aggressive behaviour patterns, however.
Interviews with survivors from Kahah reveal that in almost all cases, the hallucinations were unpleasant, with many being described as ‘nightmarish.’ Though their memories of the time under the effects of Deathglow are incomplete, many described desperately fighting for survival from monsters or demons. A few outliers, roughly 10%, report experiences that are described as not unpleasant, consistent with other hallucinogenic boosters and drugs. So far, research is ongoing to determine the reason for these outliers’ experiences.
Several physiological effects have been noticed on artificial and animal test subjects. Though the sample size is still too small to properly catalogue or assign likeliness to, these effects are (in order of observed occurrences):
1: Dilated pupils
5: Grand mal seizure
It should be noted that the grand mal seizure was recorded only once and in an artificial test subject.
A notable difference was noticed in freed slaves that were fitted with a Transcranial Microcontroller. Around 30% of those with TCMCs reported a lessened or virtually negligible reactions to Deathglow. In some cases, the patient reported being able to function normally, with no hallucinogenic effects, remaining completely lucid. Those with TCMCs reported the physical symptoms of Deathglow included paresthesia, fever, and sweating.
However, very few of slaves with TCMCs were rescued from Kahah. This data has an error of ±10%. Further research will be needed.
Notes on Insorum:
In the early stages of our research, we were hopeful that some of our efforts might yield some data on Insorum, as it was used in conjunction with Deathglow in the Kahak attacks. In the course of treatment, many freed slaves self-identified as having been infected with vitoxin and being vitoc dependant. All of these freed slaves were confirmed to be vitoxin negative during treatment at the Slave Liberation and Treatment Fortizar in Sarum Prime. There was no statistically-significant, discernable difference between the experiences of those who were infected with vitoxin and those that were not when affected by the weaponized Deathglow and Insorum mixture. It is likely that the Insorum dispersed was simply to ensure that any revolt would last longer than 24 hours. No interaction between the two is theorized at this time.
It was also hoped that some unexploded munitions might be recovered to research Blood Raider Insorum and weaponized Deathglow in a pure form. However, no such munitions were recovered.
The presence of Insorum in the attacks poses a huge risk to all non-vitoxin infected persons exposed to the gas. There is a significant risk, approaching a near medical certainty, that in the course of their lives they will be affected by a genetic disorder or cancer. A full genetic workup is recommended in 6 months, no earlier than 4 months. Thereafter, screening is recommended every 12 months.
At present, a detailed clinical study of Deathglow is needed on human patients in controlled settings. There are enormous gaps in our data, and some numbers are tentative. However, due to the immediate need for accurate data on Deathglow, we have released what we are reasonably sure of. The most important finds were our ability to neutralize the booster, and a reasonably refined LD50 dose. Hopefully, once human testing begins, a more complete paper on Deathglow and its effects can be released.